List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities)

Supplier/ Manufacturer(s) Unit III, Survey No 51, Plot No IDA, Jeedimetla, Hyderabad, Telangana, Hetero labs limited

LIST OF DELISTED PRODUCTS Not eligible for procurement with the Global Fund resources 06th of April 2018 Delisted Mar-18 Ritonavir (RTV) 0 mg Tablet Unit Survey No 51, Plot No 22-1 IDA, Jeedimetla, Hyderabad,

Sulfamethoxazole/Trimethoprim 400mg/80mg Tablets (Micro Labs Ltd), HA598. WHOPAR part 5 July 2017 LABELLING

LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGING Label/HDPE BOTTLE 1. NAME OF THE MEDICINAL PRODUCT Trimethoprim and Sulfamethoxazole Tablets BP 80 mg/400 mg 1 2. STATEMENT OF ACTIVE SUBSTANCE Each

SCIENTIFIC DISCUSSION

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

M/s. Hetero Labs Ltd.

:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir

SCIENTIFIC DISCUSSION. Darunavir

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

SCIENTIFIC DISCUSSION

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary, which are included in parts

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Aciclovir Tablets USP 400 mg * Aciclovir 400 mg Tablets Read all of this leaflet carefully before you start

Mylan Laboratories Limited F-4 & F-12, Malegaon MIDC, Sinnar Nashik Maharashtra State, India

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

SCIENTIFIC DISCUSSION. Efavirenz

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

Nevirapine 200mg Tablet WHOPAR part 3 May 2005 Updated: May 2016 PACKAGE LEAFLET

PACKAGE LEAFLET PACKAGE LEAFLET Read this entire leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lumartem * Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lumartem 1 Artemether / Lumefantrine 20mg/120mg tablets Read all of this leaflet carefully before you start

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 8 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artemether/Lumefantrine 20mg/120mg Tablets * Artemether, lumefantrine Read all of this leaflet carefully before

+91-8071808465 Modern Times Helpline Pharma http://www.moderntimesindia.com/ Modern Times Helpline pharma are exporters, suppliers, dealers & sellers of generic Gefitinib Medicines, Erlotinib Tablets-Sorafenib

Redefining The Math. The less the better WEEKS. Daclatasvir 60 mg Tablet K S

Redefining The Math 12 24 WEEKS W EE K S Hepatitis C; the most notorious of all hepatitis infections, has becoming a world threat due to its high morbidity and mortality rate. Moreover, with the prevalence

Generic HCV DAAs. Economics and sustainability. Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK

Generic HCV DAAs Economics and sustainability Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK Sunday, 23rd July 2017 Paris, France www.iasociety.org HCV DAAs can be made very

WHOPAR. SCIENTIFIC DISCUSSION

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

SCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic

PACKAGE LEAFLET. Lamivudine/Zidovudine 150/300 mg Tablets WHOPAR part 3 04/2009, version 1.0 Section 6 updated: June 2017 (Mylan Lab.

PACKAGE LEAFLET Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER Lamivudine/Zidovudine 150mg/300mg Tablets * Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.

Modern Times Helpline Pharma

+91-8079450017 Modern Times Helpline Pharma https://www.indiamart.com/geftinat/ Modern Times Helpline pharmais is Located in Delhi.We are emerging Pharma company. About Us Modern Times Helpline Pharma

Invitation to Manufacturers 16 August 2017

Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 9 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg Tablets * Emtricitabine/tenofovir disoproxil fumarate

List Of ARV Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy

Editin: Versin 147-15th f June 2018 List Of RV Pharmaceutical Prducts classified accrding t the Fund Quality ssurance Plicy The list is an verview f pharmaceutical prducts subject t the Fund Quality ssurance

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are

List Of ARV Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy

Editin: Versin 148-19th f July 2018 List Of RV Pharmaceutical Prducts classified accrding t the Fund Quality ssurance Plicy The list is an verview f pharmaceutical prducts subject t the Fund Quality ssurance

List Of ARV Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy

Editin: Versin 151-01th Nvember 2018 List Of RV Pharmaceutical Prducts classified accrding t the Fund Quality ssurance Plicy The list is an verview f pharmaceutical prducts subject t the Fund Quality ssurance

LETTERS FOR ISSUE ON

S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL

SCIENTIFIC DISCUSSION

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 8 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Linezolid 600mg Tablets 1 International Nonproprietary Name (INN): Linezolid Read all of this leaflet carefully

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 8 PATIENT INFORMATION LEAFLET 300mg Tablets * tenofovir disoproxil fumarate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Rifampicin/Isoniazid 150mg/75mg filmcoated Tablets Svizera

Abacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

Pack Size: 20 mg: Blister Pack of 150 tablets (15 x 10 Unit-dose) 40 mg/80 mg: Blister Pack of 250 tablets (25 x 10 Unit-dose)

EMERGENCY OVERVIEW Each Telmisartan Tablets contain Telmisartan and excipients generally considered to be non -toxic and non - hazardous in small quantities and under conditions of normal occupational

LETTERS FOR ISSUE ON

S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are

LETTERS FOR ISSUE ON

S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE

Paediatric ARV Procurement Working Group Progress Review at 31 December 2015

Paediatric ARV Procurement Working Group Progress Review at 31 December 2015 Version 4 March 2015 Updated with complete 2015 data from version presented at the January 27 2016 PAPWG meeting PAPWG Reporting

Copenhagen, Denmark September 2014

Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers of diagnostic products, vaccines, finished pharmaceutical products and active pharmaceutical ingredients 1 Priorities for Product Development

Efavirenz/Emtricitabine/ WHOPAR part 6 August 2011 Tenofovir disoproxil fumarate 600mg/200mg/300mg Tablets (Matrix Lab.

This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

Drug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand

Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012 GPO s Profile GPO was established in 1966.

Case 3:15-cv PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Case 3:15-cv-05982-PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 Liza M. Walsh Christine I. Gannon CONNELL FOLEY LLP One Newark Center 1085 Raymond Boulevard, 19th Floor Newark, New Jersey

Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8

LABELLING Page 1 of 8 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Bottle carton label 1. NAME OF THE MEDICINAL PRODUCT Lamivudine 150 mg Tablets * 2. STATEMENT OF ACTIVE SUBSTANCE Each film-coated tablet

REGULATORY PERSPECTIVE. Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore

1 REGULATORY PERSPECTIVE Dr. Raghunandan H V Associate Professor JSSCP, JSSU, Mysore Contents 2 1. Role of Dissolution Testing in Generic Drug Approval 2. Dissolution Testing Recommendation for Solid Oral

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 12 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lamivudine/Nevirapine/Zidovudine 30 mg/50 mg/60 mg dispersible tablets * Read all of this leaflet carefully

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

John Amis/AP Images for AIDS. Healthcare Foundation

John Amis/AP Images for AIDS Healthcare Foundation Sofosbuvir Bought in 2011 by Gilead for 11 billion: "a huge and risky bet on the next generation of hepatitis C treatments" (Reuters) Patent situation:

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution) This document should not be treated as a comprehensive guideline; it serves as a

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are

Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016

1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,

14 th SEC- Gastroenterology& Hepatology held on at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi

14 th SEC- Gastroenterology& Hepatology held on 27-08-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi 110 002 Recommendation:- The 14 th SEC ( Gastroenterology& Hepatology) meeting deliberated the

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 9 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Nevimune Baby * Nevirapine 50mg Dispersible Tablets Read all of this leaflet carefully before you start giving

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 10 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Tablets, Film Coated, 150mg/200mg/300mg * lamivudine, nevirapine, zidovudine Read all of this leaflet carefully

Artemether 20mg/lumefantrine 120mg WHOPAR part 5 12/2011 Dispersible tablets (Novartis Pharma AG), MA069 LABELLING. Page 1 of 6

LABELLING Page 1 of 6 PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARTON OF UNIT PACK 1. NAME OF THE MEDICINAL PRODUCT Coartem Dispersible Artemether/Lumefantrine 2. STATEMENT OF ACTIVE SUBSTANCE(S) Artemether

The Soft Gel Specialist

Renown PHARMACEUTICALS PVT. LTD. The Soft Gel Specialist Prestigious History Welcome to Renown Pharmaceuticals Demand for Soft Gelatin Capsules is ever increasing for Nutraceuticals, Cosmetics and Herbals.

SCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

LETTERS FOR ISSUE ON

S FOR ISSUE ON 29.11.2016 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. WELLA INDIA PVT. LTD., MUMBAI 29233, 29524 & 28513 APPROVAL 2. M/S. PROCTER & GAMBLE HOME PRODUCTS PVT. LTD.,

LETTERS FOR ISSUE ON

S FOR ISSUE ON 25.04.2017 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS

Public Assessment Report. Scientific discussion. Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/ /MR

Public Assessment Report Scientific discussion Carvedilol Aurobindo 6.25 mg and 25 mg, film-coated tablets (carvedilol) NL/H/2609/001-002/MR Date: 26 May 2014 This module reflects the scientific discussion

New Exception Status Benefits

APRIL 2018 Nova Scotia Formulary Updates New Exception Status Benefits Lenvima Updates for Hepatitis C Medications Daklinza Epclusa Harvoni Sovaldi Zepatier New Diabetic Product New Ostomy Products Nova

Decentralised Procedure. Public Assessment Report. Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack

Decentralised Procedure Public Assessment Report Memantin AbZ 10 mg/20 mg Filmtabletten ; Starterpack Memantin-ratiopharm Starterpackung 5 mg /10 mg /15 mg /20 mg Filmtabletten ;10 mg/20 mg Filmtabletten

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 6 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER 1 ethambutol hydrochloride Read all of this leaflet carefully before your child starts taking this medicine

LETTERS FOR ISSUE ON

S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL

Update on progress of MPP sublicensees

Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed

File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division

Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution

Please see the attached drug alert for onward transmission as below.

Chief Medical Officer Directorate Pharmacy and Medicines Division T: 0131-244 2528 E: irene.fazakerley@gov.scot IMMEDIATE MESSAGE TO: 1. Directors of Pharmacy 2. Medical Directors NHS Boards 18 April 2018

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Cycloserine Capsules USP 250 mg 1 Cycloserine Read all of this leaflet carefully before you start taking this

Unigel TM Case Study: Extending Soft Gelatin Capsule Benefits to Novel Fixed Dose Combinations

Unigel TM Case Study: Extending Soft Gelatin Capsule Benefits to Novel Fixed Dose Combinations Diego Monterroza, H. M. Sc, Corporate Manager, R&D Procaps S.A. Stand # 30A46 OUTLINE Fixed Dose Combinations

Public Assessment Report. Scientific discussion. Mogilarta. (Telmisartan and hydrochlorothiazide) DK/H/2306/ /DC.

Public Assessment Report Scientific discussion Mogilarta 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg tablets (Telmisartan and hydrochlorothiazide) DK/H/2306/001-003/DC 17 November 2014 This module reflects

LETTERS FOR ISSUE ON

S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Cycloserine Capsules Ph. Int. 250 mg 1 Cycloserine Read all of this leaflet carefully before you start taking

THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy

THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT Esteban Burrone Head of Policy LEARNING FROM THE HIV RESPONSE EVOLUTION OF AIDS DRUG PRICES: 2000-2008 Source: MSF (2008)

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 6 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Closerine * Cycloserine 250 mg capsules Read all of this leaflet carefully before you start taking this medicine

Lamivudine 150 mg & Zidovudine 300 mg tablets WHOPAR Part 3 August 2007 (Strides Shasun Ltd), HA291 Section 6 updated: May 2016 PACKAGE LEAFLET

PACKAGE LEAFLET Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER Lamivudine 150 mg & Zidovudine 300 mg tablets Read all of this leaflet carefully before you start taking this medicine. - Keep this

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Aciclovir 200 mg Tablets 1 Aciclovir Read all of this leaflet carefully before you start taking this medicine.

RESULTS AND DISCUSSION

RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Isoniazid/Pyridoxine hydrochloride/sulfamethoxazole/trimethoprim * Read all of this leaflet carefully before

Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines:

Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: 1. Summary statement of the proposal for inclusion, change or

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Oseltamivir (as phosphate) 75mg Capsules * Oseltamivir Read all of this leaflet carefully before you start taking this

Procurement, selection, prequalification, pricing and monitoring of medicines

Procurement, selection, prequalification, pricing and monitoring of medicines Richard Laing Medicines Information and Evidence for Policy, Essential Medicines and Pharmaceutical Policies World Health Organization

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

Welcome to Galenicum! APRIL, 2013

Welcome to Galenicum! APRIL, 2013 Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3 Who

Free Trial Future Generics Database

API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide

TODAY LETTER DATED

TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY

PDF of Trial CTRI Website URL -

Clinical Trial Details (PDF Generation Date :- Wed, 22 Aug 2018 08:47:30 GMT) CTRI Number CTRI/2009/091/000605 [Registered on: 18/01/2011] - Last Modified On 15/02/2013 Post Graduate Thesis Type of Trial

Products to which COPP granted

List of Companies whose Ayurvedic Products were granted Certificate of Pharmaceutical Products (COPP) as per WHO GMP Certification Scheme by Central Drugs Standard Control Organisation as on September

Public Assessment Report. Scientific discussion. Bloxazoc 25 mg, 50 mg, 100 mg and 200 mg prolonged-release tablets Metoprolol succinate

CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Bloxazoc 25 mg, 50 mg, 100 mg and 200 mg prolonged-release tablets Metoprolol succinate HR/H/0103/001-004/DC Date: 16.2.2016 This

WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization

SOP 408.4 Annex C 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract

Priority essential medicines: identifying products. Dr Suzanne Hill September 2010

Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO

Lekpharm JLLC, , Minskaya region, Logoysk, Minskaya str. 2a. Lekpharm JLLC, , Minskaya region, Logoysk, Minskaya str.

List of the medicines recommended for registration by N 11-2/18 meeting decision of the Pharmacological Council of MoH of A dated on November 30, 2018 President E. Amroya N Trade name International nonproprietary

Procurement policies and requirements

Procurement policies and requirements JOINT UNICEF, UNFPA & WHO meeting with manufacturers, Copenhagen 22-24 Sep 2014 ELODIE JAMBERT International Pharmacist Coordinator Médecins Sans Frontières (MSF)

Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines:

Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: 1. Summary statement of the proposal for inclusion, change or

SCIENTIFIC DISCUSSION. AkuriT-3 Tablets*

SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

Public Assessment Report. Scientific discussion. Pregabalin Orion (pregabalin) SE/H/1440/01-07/DC

Public Assessment Report Scientific discussion Pregabalin Orion (pregabalin) SE/H/1440/01-07/DC This module reflects the scientific discussion for the approval of Pregabalin Orion. The procedure was finalised

Public Assessment Report. Scientific discussion. Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets.

Public Assessment Report Scientific discussion Tadalafil 1A Pharma 2.5 mg, 5 mg, 10 mg and 20 mg, film-coated tablets (tadalafil) NL/H/3634/001-004/DC Date: 24 May 2017 This module reflects the scientific

Public Assessment Report. Scientific discussion. Aktiprol 50 mg, 100 mg, 200 mg and 400 mg tablets. (Amisulpride) DK/H/2386/ /DC

Public Assessment Report Scientific discussion Aktiprol 50 mg, 100 mg, 200 mg and 400 mg tablets (Amisulpride) DK/H/2386/001-004/DC 21 January 2016 This module reflects the scientific discussion for the